(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's forecast annual revenue growth rate of 35.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Newamsterdam Pharma Co Nv's revenue in 2025 is $47,961,052.On average, 3 Wall Street analysts forecast NAMS's revenue for 2025 to be $2,196,356,240, with the lowest NAMS revenue forecast at $2,196,356,240, and the highest NAMS revenue forecast at $2,196,356,240. On average, 2 Wall Street analysts forecast NAMS's revenue for 2026 to be $1,482,540,462, with the lowest NAMS revenue forecast at $647,925,091, and the highest NAMS revenue forecast at $2,317,155,833.
In 2027, NAMS is forecast to generate $14,804,099,964 in revenue, with the lowest revenue forecast at $3,960,030,301 and the highest revenue forecast at $27,614,787,006.